Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.

Abstract Older age has been shown to adversely impact overall survival (OS) in chronic lymphocytic leukemia (CLL) however, prior population-based studies did not analyze the impact of cytogenetic abnormalities or were prior to the availability of ibrutinib. Objectives i) We sought to compare outcomes of patients based on their age at treatment to examine if older age has an impact on OS in patients who were treated during the period when fludarabine-rituximab was the standard upfront therapy and when ibrutinib was first introduced and ii) compare outcomes based on whether the patient received primary treatment at an academic or community-based centre. Methods The BC Provincial CLL Database, a population-based database was used to include patients who have received treatment in British Columbia (BC), Canada between 2004 and 2016. Results A total of 1122 patients were included ( Conclusions Older age but not treatment-institution type adversely impacts overall survival and CLL survival in treated patients in BC.